What changed
What changedThe European Medicines Agency recommended adding the option of a Bexsero vaccine booster dose for individuals aged 10 years and older. The change applies to patients who completed primary immunization at least two years earlier.

What changedGSK plc has agreed with Chimagen Biosciences to acquire full global rights to a trispecific T cell engager. The total potential value of the deal is up to $750 million. The company says the programme is expected to enter clinical trials in 2027.

Company history
October 2026
GSK plc: 12 recorded developments from 7 official sources in 2026-10.
- 2026-09-22: An Independent Non-Executive Director purchased 936 Ordinary Shares of GSK plc at £18.8100 per share. Source
- 2026-09-24: Maya Martinez-Davis, President, US, acquired notional ADS within her GSK Executive Supplemental Savings Plan account. Source
- 2026-09-24: The transaction involved a price of $50.7200 and a volume of 9.414 American Depositary Shares (ADS). Source
- 2026-09-24: The transaction is a single transaction with no aggregated volume or price information applicable. Source
- 2026-10-01: The total number of voting rights figure may be used by shareholders as the denominator for calculations to determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparen Source
- 2026-10-06: The notification covers the date range from 7 August 2026 to 2 October 2026 for the admission of securities to trading. Source
- 2026-10-08: Wendy Becker, an independent Non-Executive Director of GSK plc, has been appointed as a Non-Executive Director of Tesco PLC with effect from 1 November 2026. Source
- 2026-10-13: Acquisition of Ordinary Shares under the Company's Share Reward Plan at a price of £17.6539 for a volume of 7 (partnership shares) and £17.6539 for a volume of 7 (matching shares). Source
- 2026-10-14: Shobie Ramakrishnan, Chief Digital and Technology Officer, has an interest in American Depositary Shares (‘ADS’) of GSK plc Source
- 2026-10-14: David Redfern, President, Corporate Development, has an interest in Ordinary shares of 31 ¼ pence each (Ordinary Shares) of GSK plc Source
- 2026-10-14: David Redfern, President, Corporate Development, increased notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan Source
- 2026-10-14: Julie Brown acquired Ordinary Shares following the re-investment of dividends paid on 8 October 2026 on Ordinary Shares held in the Company’s Performance Share Plan subject to a 2-year holding period Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| Fidelity (FMR) | 64,920,926 | $3,127,240,971 | -0.1% | Q3 2026 |
| Wellington Management | 9,650,852 | $464,881,541 | -15.3% | Q3 2026 |
| State Street | 5,940,605 | $288,838,444 | -0.3% | Q3 2026 |
| BlackRock | 3,408,608 | $164,192,624 | -5.8% | Q3 2026 |
| D. E. Shaw & Co. | 1,954,472 | $94,146,916 | +91.7% | Q3 2026 |
| Citadel Advisors | 1,165,967 | $56,164,631 | +669.2% | Q3 2026 |
| Bridgewater Associates | 548,661 | $26,429,000 | +8.8% | Q3 2026 |
| Renaissance Technologies | 466,340 | $22,463,598 | +49.8% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 200,000 | $10,484,000 | — | Q2 2026 |
| Two Sigma Investments | 186,489 | $8,983,175 | +162.7% | Q3 2026 |
| T. Rowe Price | 6,712,097 | $323,323 | -3.1% | Q3 2026 |
| Millennium Management | 4,067 | $224,458 | — | Q1 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.